Empirical Financial Services LLC d.b.a. Empirical Wealth Management Boosts Position in Hologic, Inc. (NASDAQ:HOLX)

Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its stake in Hologic, Inc. (NASDAQ:HOLX) by 11.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 68,427 shares of the medical equipment provider’s stock after buying an additional 6,986 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management’s holdings in Hologic were worth $4,933,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in the stock. Wolff Wiese Magana LLC bought a new stake in shares of Hologic during the third quarter valued at approximately $25,000. General Partner Inc. bought a new stake in Hologic during the 4th quarter valued at $26,000. Groupama Asset Managment lifted its holdings in shares of Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 2,999 shares during the period. Sunbelt Securities Inc. bought a new position in shares of Hologic during the 2nd quarter worth $37,000. Finally, First Horizon Advisors Inc. increased its stake in shares of Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 134 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Hologic Stock Up 0.5 %

HOLX stock opened at $71.02 on Monday. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. Hologic, Inc. has a 52 week low of $68.61 and a 52 week high of $84.67. The stock has a market capitalization of $16.03 billion, a PE ratio of 21.33, a price-to-earnings-growth ratio of 2.43 and a beta of 0.97. The firm has a 50 day moving average of $74.01 and a 200 day moving average of $78.27.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.01. The firm had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.89 earnings per share. Sell-side analysts forecast that Hologic, Inc. will post 4.27 earnings per share for the current year.

Insider Activity

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 1.88% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on HOLX shares. Jefferies Financial Group assumed coverage on shares of Hologic in a research report on Tuesday, December 10th. They set a “hold” rating and a $85.00 target price on the stock. Morgan Stanley lowered their target price on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Raymond James lifted their price target on Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. Leerink Partners decreased their price objective on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Finally, Evercore ISI lifted their target price on Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a research note on Tuesday, October 1st. Seven research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Hologic has an average rating of “Moderate Buy” and an average price target of $88.92.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.